ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.921,17
-0,41%
S&P 500
5.905,50
0,63%
Dow Jones
42.547,20
0,37%
Euro vs US Dollar
1,0301
0,32%
Bitcoin
97.079,15
0,19%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. ADC Therapeutics SA (ADCT)

  7. ADC Therapeutics SA (ADCT) News

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:ADCT
DatumZeitQuelleÜberschriftSymbolFirma
02/01/202522h05PR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
30/12/202422h30PR Newswire (US)ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell LymphomaNYSE:ADCTADC Therapeutics SA
11/12/202413h30PR Newswire (US)ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaNYSE:ADCTADC Therapeutics SA
10/12/202402h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
10/12/202402h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
10/12/202402h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
09/12/202413h30PR Newswire (US)ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaNYSE:ADCTADC Therapeutics SA
06/12/202413h30PR Newswire (US)ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical TrialNYSE:ADCTADC Therapeutics SA
02/12/202422h30PR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
07/11/202416h44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
07/11/202413h54Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
07/11/202413h30PR Newswire (US)ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdateNYSE:ADCTADC Therapeutics SA
05/11/202415h47PR Newswire (US)ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual MeetingNYSE:ADCTADC Therapeutics SA
04/11/202413h15PR Newswire (US)ADC Therapeutics to Present at November Investor ConferencesNYSE:ADCTADC Therapeutics SA
01/11/202421h05PR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
31/10/202412h15PR Newswire (US)ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024NYSE:ADCTADC Therapeutics SA
01/10/202422h05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
23/09/202422h39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:ADCTADC Therapeutics SA
23/09/202422h35Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:ADCTADC Therapeutics SA
13/09/202422h16Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNYSE:ADCTADC Therapeutics SA
03/09/202422h05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
03/09/202413h15GlobeNewswire Inc.ADC Therapeutics to Present at Upcoming Investor ConferencesNYSE:ADCTADC Therapeutics SA
14/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:ADCTADC Therapeutics SA
06/08/202422h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:ADCTADC Therapeutics SA
06/08/202416h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
06/08/202413h37Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
06/08/202413h30GlobeNewswire Inc.ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateNYSE:ADCTADC Therapeutics SA
01/08/202422h05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
30/07/202413h15GlobeNewswire Inc.ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024NYSE:ADCTADC Therapeutics SA
08/07/202408h00GlobeNewswire Inc.Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentNYSE:ADCTADC Therapeutics SA
 Showing the most relevant articles for your search:NYSE:ADCT

Kürzlich von Ihnen besucht

COIN
ADAUSD
Cardano
AMEX
XLF
Financial Select Sector
TG
432
Arbor Metals
AMEX
XLV
Health Care Select Sector
NASDAQ
AAPL
Apple
COIN
AVAXUSD
Avalanche
FX
EURGBP
Euro vs Sterling
COIN
SOLUSD
Solana
TG
RHM
Rheinmetall
FX
EURUSD
Euro vs US Dollar
COIN
XRPUSD
Ripple
AMEX
XLE
Energy Select Sector SPDR
FX
EURJPY
Euro vs Yen
COIN
DOGEUSD
Dogecoin
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten